Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.64 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.64 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.64 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | GGH | Q92820 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953437 | 0.89 | GNPAT (0.56) | FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL14310838 | 0.85 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL14719913 | 0.85 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL14729416 | 0.85 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL1533825 | 0.83 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL6270974 | 0.83 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL4572551 | 0.83 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL6310597 | 0.82 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL6307131 | 0.82 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL16350092 | 0.82 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLAGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218858-B | 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-06-18 | — | — | CN | disclosed |
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2023-04-13 | — | — | US | disclosed |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | MEDICINSK FORSKNING (SE) | 2021-02-25 | — | — | US | disclosed |
| EP-3781554-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | Thomas Helledays stiftelse för medicinsk forskning (SE) | 2021-02-24 | — | — | EP | disclosed |
| CN-112218858-A | 2, 6-diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019201991-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FOLH1 282/4885NAALAD2 635/4885RIMKLA 3351/4885 |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FOLH1 315/4885NAALAD2 747/4885RIMKLA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.